Kelly CRISPR & Gene Editing Technology ETF

Why Invest in XDNA ETF

XDNA is designed to capitalize on the next generation of healthcare by investing in companies disrupting the genomic and life science industries.

Invest Now


Data as of TBD

Holdings are subject to change


Limited Operating History Risk. The Fund is a recently organized investment company with a limited operating history. As a result, prospective investors have a limited track record or history on which to base their investment decision.

DNA Modification Technology Company Risk. DNA modification technology companies face intense competition, and products and services with a potentially short product life. These companies will generally require large amounts of capital expenditures on research and development, with no guarantee that the product or service would be successful. They may be heavily dependent on intellectual property rights. The laws related to these rights can vary and there is no guarantee that a company will be able to successfully protect their intellectual property rights. These companies, like other health care companies, are subject to various government and regulator oversight that could hamper or impede their operations.

Foreign Securities Risk. Investments in non-U.S. securities involve certain risks that may not be present with investments in U.S. securities. For example, investments in non-U.S. securities may be subject to risk of loss due to foreign currency fluctuations or to political or economic instability.


Investing involves risk including possible loss of principal.

Before investing carefully consider a funds investment objective, risks, charges, and expenses contained in the prospectus available at KELLY ETFs. Read carefully before investing.

Distributor: Foreside Fund Services, LLC.